1.	F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer Phase: Phase II Type: Diagnostic Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00270, 6590, P30CA015704, UWCC-6590, 8052, NCT00602043
2.	PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer Phase: No phase specified Type: Biomarker/Laboratory analysis, Diagnostic Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 6213, P30CA015704, UWCC-6213, UWCC-06-0445-H/D, CDR0000492255, NCT00362973
3.	Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer Phase: No phase specified Type: Diagnostic Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: BR-1-0093, NCT00358098
4.	Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer Phase: No phase specified Type: Diagnostic Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 05-088, NCT00647790
5.	Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy Phase: No phase specified Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 6856, NCI-2010-01289, NCT01153672